<DOC>
	<DOCNO>NCT01498913</DOCNO>
	<brief_summary>This study conduct Asia . The aim study review safety efficacy Novonorm® ( repaglinide ) post-marketing use .</brief_summary>
	<brief_title>Observational Study NovoNorm® Subjects With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<criteria>Type 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>